Compare BridgeBio Pharma Inc (BBIO) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? BridgeBio Pharma Inc trades at $84.79 (market cap $16.36B), while State Street Technology Select Sector SPDR ETF trades at $189.19. Which is the better fit depends on your goals.
| BBIO | XLK | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $198.21 |
52-Week Low | $47.29 | $127.49 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.
The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.
XLK trades at $189.38, up 1.64% with strong technical momentum as moving averages signal bullish conditions. The Technology Select Sector SPDR Fund shows institutional interest with record sector ETF inflows of $25 billion in July 2026 (ETF Trends, 2026-08-10). Recent earnings strength from holdings like Microsoft supports the fund's performance, though RSI levels suggest potential near-term overbought conditions.
Outlook remains positive given sector earnings growth and AI-driven momentum, but risks include concentration in mega-cap stocks and valuation concerns. The fund's heavy reliance on top holdings creates sensitivity to individual company performance, requiring careful monitoring of diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
